Biostock: CombiGene’s CEO on this summer’s news

2021   2020   2019   2018   2017   2016   2015 "The gene therapy company CombiGene ended July with two significant pieces of news. Firstly, the company has started GMP production of the drug candidate CG01 for the first clinical study that begin next year. Secondly,...

read more

CombiGene celebrates International Epilepsy Day

News 2021 2021   2020   2019   2018   2017   2016   2015 The International Epilepsy Day is held on the second Monday of February each year. There are 50 million people in the world living with epilepsy, of which 81,000 lives in Sweden. The purpose of International...

read more

CombiGene headhunts again

News 2021 2021   2020   2019   2018   2017   2016   2015 With experience from Medical Affairs at MERCK and early drug development at Karo Bio, a solid background in research from a doctoral thesis at Karolinska Institutet and postdoctoral research at Mount Sinai...

read more

BioStock interviews Martin Linhult, CombiGene’s new CMC expert

News 2021 2021   2020   2019   2018   2017   2016   2015 BioStock has spoken with the newly recruited CMC expert Martin Linhult who, with his long experience of bringing pharmaceuticals to the market, will primarily focus on the manufacturing process of CG01, which is...

read more

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99



CombiGene AB, Agavägen 52A, SE-181 55 Lidingö


Linked In     Twitter      Facebook